Form 8-K · Current Report · Filed 2024-06-18
Ionis Pharmaceuticals Expands Licensing for Investigational HAE Medicine with Otsuka
Ionis Pharmaceuticals, Inc. has entered into an amended and restated license agreement with Otsuka Pharmaceutical Co., Ltd., granting Otsuka exclusive rights across the Asia-Pacific region and Europe to commercialize donidalorsen, an investigational RNA-targeted prophylactic medicine for hereditary angioedema (HAE). Ionis will maintain responsibility for the development of donidalorsen, while Otsuka will handle territory-specific development, regulatory filings, and commercialization. The agreement includes an upfront payment of $20 million and potential milestone payments and royalties for Ionis.
- Filer
- Ionis Pharmaceuticals Inc. IONS · NASDAQ
- Filed
- Accession
- 0001140361-24-030447
- CIK
- 0000874015
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Entry into a Material Definitive Agreement
Financial Statements and Exhibits
Market reaction
Close before filing
$40.76
Next session
+0.1%
Since filing
+27.0%
Latest close
$51.77
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from IONS reporting the same item, with the next session's move:
Exhibits (1)
About Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc. is a biotechnology company focused on discovering and developing RNA-targeted therapeutics. The primary mission of Ionis is to harness its expertise in antisense oligonucleotide technology to address complex genetic disorders. Ionis is pioneering in the field of RNA-targeted drug discovery, aiming to treat a wide range of diseases, including neurological, cardiovascular, metabolic, and cancer-related conditions. Notably, the company has a robust pipeline of drugs in various stages of development and partnerships with leading pharmaceutical companies to expand the reach and impact of its therapeutic discoveries. As an innovative entity in the biotechnology sector, Ionis Pharmaceuticals plays a significant role in advancing medical treatments that target the underlying genetic causes of diseases, thereby offering new hope and potential solutions to patients worldwide. Its advancements contribute substantially to the growth and evolution of personalized medicine, emphasizing the importance of genetic research in modern healthcare.
Never miss another IONS filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.